one course each of MACE (mitozantrone on days 1, 3 and 5, cytosine arabinoside on days 1-10, etoposide on days 1-5) and ICE (idarubicin on days 1 and 2, cytosine arabino-A 40-year-old woman underwent allogeneic peripheral blood stem cell transplantation for relapsed AML-M6.
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On physical examination, she was apyrexial, blood pressure was 150/90, pulse 80 per min and there was mild jaundice. The pupils were reactive and there was no afferent pupillary Case report defect. Visual acuity was 0/20 in each eye and confrontational visual field testing revealed that there was no A 40-year-old woman was diagnosed as having acute response to visually threatening gestures. There was no evimyeloid leukaemia-FAB classification M6 in October, dence of any nystagmus. Ocular motility and fundoscopic 1995. She was treated on the Medical Research Council examination were normal. The rest of the neurological AML-12 trial and received two courses of ADE chemoexamination was normal. therapy (cytosine arabinoside on days 1-10, daunorubicin A blood count showed haemoglobin of 9.9 g/dl, WBC on days 1, 3 and 5, etoposide on days 1-5) followed by count of 2.8 × 10 mal 48 h later. She complained of drowsiness but was rousable and oriented. Visual acuity was 20/20 corrected in each eye. Visual field testing did not reveal any defects and fundoscopic examination was normal. The blood pressure was 130/80. A repeat MRI scan done 1 week later showed resolution of the occipital lobe abnormalities but the small focal abnormality in the right frontal white matter persisted. She was discharged on day +41 following the transplant. Currently, she is alive and well at day +200 following the transplant and on no medication.
Discussion
The incidence of cyclosporin A neurotoxicity has been variably reported as being between 10 and 25%. 5 A variety of clinical presentations is seen. Generalised motor seizures is one of the more common presentations. Other features that have been reported include altered mental function, confusion, anxiety and visual hallucinations. Atkinson et al 4 described spinal cord and cerebellar-like syndromes associated with the use of cyclosporin A in allogeneic bone marrow transplant recipients. Cortical blindness is a rare manifestation of cyclosporin A neurotoxicity observed mainly in patients undergoing liver and bone marrow transplantation. de Groen et al.
5 described a syndrome of encephalopathy, seizures and white matter changes in liver with reversible posterior encephalopathy due to diverse causes. Rubin and Kang 7 reported on acute cortical blindness complicating cyclosporin A toxicity in a BMT patient. function tests showed hyperbilirubinemia -bilirubin Noll and Kulkarni 8 described complex visual hallucinations 120 mol/l (NR 0-22 mol/l) and hypoalbuminemiain a BMT recipient taking cyclosporin A for GVHD. There albumin 30 g/l (NR 35-46 g/l). The remaining tests of liver have been no previous reports of cyclosporin A neurotoxifunction were normal. The whole blood cyclosporin A level city in association with peripheral stem cell allografts. was 688 g/l (reference range 100-250 g/l). An MRI scan
The central nervous system side-effects of cyclosporin A of the head showed diffuse subtle cortical abnormality in are more frequently seen in patients with high levels of both occipital lobes and a further small focal abnormality cyclosporin A in whole blood or plasma. They are more present in the white matter of the right frontal lobe but frequently seen in association with concurrent high-dose no abnormal enhancement was seen following intravenous methyl prednisolone treatment, hypertension, hypomagnecontrast medium (Figure 1 ). No evidence of acute haemorsemia, aluminium overload in renal transplant patients and rhage was present.
low serum cholesterol levels in liver transplant patients.
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A diagnosis of cyclosporin A toxicity with secondary However, they have also been reported in patients with encephalopathy and cortical blindness was made. The therapeutic levels of cyclosporin A and none of the above cyclosporin A and methyl prednisolone were discontinued. risk factors. She was treated with intravenous phenytoin, sublingual Although the initial cyclosporin A levels were high in nifedipine and magnesium replacement. Serial cyclosporin our patient, she also had other multiple risk factors -con-A levels were as follows: current high-dose methyl prednisolone treatment, hypertenDay +18 22.7.96 526 g/l sion and hypomagnesemia. One unusual feature was the Day +19 23.7.96 688 g/l (date of onset of blindness) nature of the abnormalities on MRI. Other reports have sugDay +20 24.7.96 449 g/l gested that the abnormalities on neuroimaging have preDay +21 25.7.96 388 g/l (date of resolution of blindness) dominantly involved the white matter in the posterior porDay +22 26.7.96 261 g/l tions of the cerebral hemispheres, especially bilaterally in Day +23 27.7.96 164 g/l the parieto-occipital regions. 1 The grey matter is additionDay +24 28.7.96 150 g/l ally involved in a minority of patients. The changes tend Day +25 29.7.96 103 g/l to be symmetric but the degree of involvement can be Day +26 30.7.96 106 g/l asymmetric. In our patient, however, the changes involved mainly the occipital cortices bilaterally and the white matter Methotrexate was substituted for cyclosporin A for graftversus-host disease prophylaxis. She was given methotrexwas relatively spared. The mechanism by which cyclosporin A causes central ate 25 mg/m 2 intravenously weekly for 6 weeks. Her vision gradually improved over the ensuing 2 days and was nornervous system toxicity is not clear. blood-brain barrier causes cerebral oedema. 547-553. Another point that warrants highlighting is that many monitoring of therapeutic levels of cyclosporin A, especially when used in association with other risk factors.
